Sequana Medical secures EUR 10 million loan facility with Kreos Capital
20. Juli 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION20 July 2022, 07:00 CET Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels:...
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
19. Juli 2022 01:02 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 July 2022, 07:00 am CEST DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with...
Doug Kohrs appointed to Sequana Medical Board of Directors
19. Juli 2022 01:00 ET
|
Sequana Medical NV
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...
Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
27. Mai 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 May 2022, 06:00 pm CEST Ghent, Belgium – 27 May 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the...
Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2022
27. April 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 April 2022, 07:00 am CEST Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
Sequana Medical announces 2021 Full Year Results and 2022 Outlook
12. April 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION12 April 2022, 07:00 CET alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months...
Sequana Medical to present at Needham’s Healthcare Conference and attend Kempen’s Life Sciences Conference in April 2022
08. April 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 8 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study
05. April 2022 01:00 ET
|
Sequana Medical NV
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to...
Sequana Medical Notice of 2021 Full Year Results and Business Update
31. März 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 31 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver...
Transparency Notifications from Shareholders
28. März 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 28 March 2022, 6 p.m. CET Ghent, Belgium – 28 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in...